好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Anti-NMDA-Receptor Encephalitis: Case Series and Analysis
Neuro-oncology
P07 - (-)
018
BACKGROUND: Anti-NMDA-receptor encephalitis is an immune-mediated syndrome that is increasingly being recognized cause of seizure or psychiatric conditions requiring hospital admission. Previous reports have described young females presenting with symptom of personality changes, focal neurological deficits, seizures, or autonomic dysfunction. In the past it has often reported in patients with ovarian teratomas.
DESIGN/METHODS: Case Series Analysis.
RESULTS: We describe an array of clinical presentations of anti-NMDA-R encephalitis over the past several years at McMaster University. Complex partial seizures, personality change, and psychiatric symptoms were common presentations of this disorder. A majority of patients showed dramatic improvement with 5 day course of IVIG at 2g/kg. Many of the patients had no underlying tumour identified at time of presentation.
CONCLUSIONS: These findings indicate antibody-associated immune response against NR1/NR2 heteromers of the NMDA receptor (NMDAR) is a potentially severe yet reversible medical condition. Often it may precede the detection of any tumor such as ovarian teratoma by several years and therefore follow-up screening is indicated.
Authors/Disclosures
Rick Magun, MD (UBMD Neurology/ SUNY BUFFALO)
PRESENTER 		Dr. Magun has nothing to disclose.
Sandra E. Black, MD, FAAN (Sunnybrook Health Science Center) Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.